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Abstract
Background: Human Bronchial epithelial cells (hu-BEC) have been claimed to play a significant
role in the pathogenesis of chronic inflammatory airway diseases like COPD. In this context IL-8
and GM-CSF have been shown to be key cytokines. Some antibiotics which are routinely used to
treat lower respiratory tract infections have been shown to exert additional immunomodulatory
or anti-inflammatory effects. We investigated whether these effects can also be detected in hu-BEC.
Methods: Hu-BEC obtained from patients undergoing lung resections were transferred to air-
liquid-interface (ALI) culture. These cultures were incubated with cefuroxime (CXM, 10-62.5 mg/
l), azithromycin (AZM, 0.1-1.5 mg/l), levofloxacin (LVX, 1-8 mg/l) and moxifloxacin (MXF, 1-16 mg/
l). The spontaneous and TNF-α (10 ng/ml) induced expression and release of IL-8 and GM-CSF
were measured using PCR and ELISA in the absence or presence of these antibiotics.
Results: The spontaneous IL-8 and GM-CSF release was significantly reduced with MXF (8 mg/l)
by 37 ± 20% and 45 ± 31%, respectively (both p < 0.01). IL-8 release in TNF-α stimulated hu-BEC
decreased by 16 ± 8% (p < 0.05) with AZM (1.5 mg/l). With MXF a concentration dependent
decrease of IL-8 release was noted up to 39 ± 7% (p < 0.05). GM-CSF release from TNF-α
stimulated hu-BEC was maximally decreased by 35 ± 24% (p < 0.01) with MXF (4 mg/l).
Conclusion: Using ALI cultures of hu-BEC we observed differential effects of antibiotics on
spontaneous and TNF-α induced cytokine release. Our data suggest that MXF and AZM, beyond
bactericidal effects, may attenuate the inflammatory process mediated by hu-BEC.
Background
Antimicrobial agents of different classes - e.g. beta-
lactames, quinolones, and macrolides - are standard of
care in the treatment of respiratory tract infections. In
addition to their antimicrobial activity some of these anti-
biotics, especially macrolides and fluoroquinolones, have
immunomodulatory effects [1-3]. These anti-inflamma-
tory or immunomodulatory capabilities have been dem-
onstrated in human cells, cell lines, and in animal
experiments [1,4-7].
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nolones in lung cells and in alveolar macrophages a tar-
geted modulation of the inflammatory reaction could be
of additional therapeutic benefit by attenuation of the
inflammatory process in lower respiratory tract infection
(LRTI) as well as in chronic non-infectious airway diseases
like COPD [8-10].
Airway epithelial cells have been shown to be of crucial
importance in the pathogenesis of inflammatory airway
diseases [11]. In addition to antimicrobial activities, mac-
rolides directly affect pulmonary host defence like the
neutrophil activation and the immune cell function.
These effects are mediated by an alteration of cytokine and
chemokine release, as has been demonstrated in vitro and
ex vivo [2,12]. Moreover, macrolides like azithromycin
are already clinically used in chronic respiratory diseases
like diffuse panbronchiolitis (DPB), cystic fibrosis despite
they have no antimicrobial activity against Pseudomonas
aeruginosa. A beneficial effect on bacterial virulence fac-
tors by inhibiting quorum-sensing, a mechanism of bacte-
rial communication, is described for macrolides and
quinolones as well [13-17].
Additionally, immunomodulatory effects of macrolides
are used in bronchiolitis obliterans syndrom after bone
marrow transplantation and lung transplantation which
are diseases without infectious background [12,18,19].
There are many studies, which elucidated the immu-
nomodulatory effects of macrolides in human cells
[20,21]. However, the underlying intracellular mecha-
nisms of immunomodulation by macrolides are not com-
pletely understood yet [20,21].
Similarly to macrolides, immunomodulatory effects have
been shown for fluorquinolones in a variety of cells of the
immune system and in lung epithelial cells. These effects
were especially pronounced in fluorquinolones with a
cyclopropyl-moiety at position N1 like ciprofloxacin and
moxifloxacin [1]. Moreover, expression of pro-inflamma-
tory cytokines in human monocytes is suppressed by
moxifloxacin in vitro and in vivo in an animal model of
inflammation [4,7]. Beside the modulation of cytokine
release from cells of the immune system it has been
shown, that quinolones reduce pro-inflammatory activi-
ties of respiratory epithelial cell lines, thus potentially
influencing pulmonary host defence [5,6].
Therefore, we investigated the modulation of cytokine
release from primary human bronchial epithelial cells in
air-liquid interface culture by different antibiotics.
Methods
Preparation of air-liquid interface cultures of human 
bronchial epithelial cells (hu-BEC)
The human bronchial epithelial cells were harvested from
patients undergoing lung surgery for cancer resection or
transplantation [22,23]. Written informed consent was
obtained from each patient according to the recommen-
dations of the local ethic committee and there was an
approval of our institutional review board. After prepara-
tion the resected bronchi were incubated for 24 h at 4°C
in DMEM (Dulbeccos Modified Eagle Medium, Invitro-
gen, USA) and DTT (Dithio-Threitrol, Invitrogen, USA)
containing penicillin G (Jenapharm, Germany), strepto-
mycine (Rotexmedica, Germany), gernebcin (Infectop-
harm, Germany), imipenem (MSD, Germany) and
amphotericin b (Bristol-Myer-Sqibb, Germany). Thereaf-
ter the bronchi were treated with protease Type XIV
(Sigma, Germany) for 24 h at 4°C and rinsed several
times with DMEM to wash out the epithelial cells. Then
the cells were grown to 80% confluence with airway epi-
thelial cell growth medium (Promocell, Germany) and
after treatment with trypsin (0.05%, Invitrogen, USA) the
cells were transferred on a collagenised PTFE membrane
(polytetrafluorethylen, Millipore, USA) of 6-well plates
(Corning Costar, USA) at a concentration 2 × 106 cells/ml
and grown with DMEM containing HAM-12 (Invitrogen,
USA), Ultroser G (Pall Life Sciences, France) and antibiot-
ics (penicillin 100 U/ml and streptomycin 100 μg/ml,
Invitrogen) at 37°C in 5% carbon dioxide/air. The super-
natant was removed after 2 days and the cells were air-
lifted. After another 14.0 ± 2.6 days these air-liquid-inter-
face cultured cells expressed their characteristic bronchial
polarity (see Fig. 1). Cultures were considered confluent
and differentiated if the Rt was stable and > 500 Ω/cm2
measured by Ohmmeter (EVOM, World Precision Instru-
ments, USA).
Incubation experiments
To characterize spontaneous cytokine-expression and
release of hu-BEC, we incubated air-liquid-interface (ALI)
cultures with buffer or with cefuroxime (62.5 mg/l), azi-
air-liquid-interface-culture (schematic); HE-stain of an air-liq-uid- nterface-culture with character stic polarityFigur  1
air-liquid-interface-culture (schematic); HE-stain of 
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floxacin (8 mg/l) for 24 h. Thereafter, the basolateral
medium of each well was collected and frozen at -20°C.
The cells were lysed with Trizol (GIBCO, Germany) and
the lysates were stored at -80°C.
To investigate cytokine-expression and release of hu-BEC
under pro-inflammatory conditions the ALI cultures cells
were pre-incubated for 24 hours with buffer or with vari-
ous antibiotics at different concentrations (see Table 1)
and stimulated with TNF-alpha (10 ng/ml) for another
24-h incubation. Thereafter, the basolateral medium of
each well was collected and frozen at -20°C. The cells
were lysed with Trizol reagent (GIBCO, Germany) and the
lysates were frozen at -80°C.
To determine, whether there is a concentration-dependent
effect of these antibiotics, we used a range of concentra-
tions (see Table 1), which are reached in humans in vivo
covering therapeutic levels in human serum, in broncho-
alveolar lavage fluid, or in bronchial tissue [8,9].
Moxifloxacin and azithromycin was a generous gift from
Bayer Healthcare Germany and Pfizer Germany. Cefurox-
ime and levofloxacin were purchased form Sanofi-Aventis
(France) and DeltaSelect (Germany), respectively.
ELISA
IL-8 and GM-CSF were measured in basolateral medium
using enzyme-linked immunosorbent assays (ELISA)
(both R&D Systems, USA) as previously described [24].
RNA Extraction
RNA was extracted with Trizol according to the methods
recommended by the manufacturer and frozen at -80°C.
For analysis frozen epithelial cell lysates were re-dissolved
in water. Total RNA yield was calculated by measuring the
absorbance at 260 and 280 nm (assuming that A260 of 1 =
40 μg RNA). RNA integrity was judged by determining the
ratio of A260/A280. Only samples with an A260/A280 ratio
from 1.6 to 2.0 were used for the subsequent measure-
ments.
First-strand complementary deoxyribonucleic acid 
synthesis by reverse transcription
The RNA was transferred in cDNA with the cDNA synthe-
sis kit (Fermentas, Germany) following the instruction of
the manufacturer. The first-strand cDNA was stored at -
80°C.
Semiquantitative polymerase chain reaction
A sample of 1 μl of cDNA was used for each 20 μl PCR
reaction. Primer sets used for the amplification of
cytokines and the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were as follows:
GAPDH (MWG-Biotech, Germany): Forward: 5'-TGA
AGG TCG GAG TCA ACG GAT TTG GT-3'; Reverse: 5'-CAT
GTG GGC CAT GAG GTC CAC CAC-3', (size of PCR prod-
uct: 900 base pair [bp]).
IL-8 (MWG-Biotech, Germany): Forward: 5'-ATT TCT
GCA GCT CTG TGT GAA-3'; Reverse: 5'-TGA ATT CTC
AGC CCT CTT CAA-3', (size of PCR product: 255 bp).
Table 1: Concentrations of cefuroxime (CXM), azithromycin (AZM), levofloxacin (LVX) and moxifloxacin (MXF) used for incubation 
experiments
Concentration TNF-α(10 ng/ml) IL-8 GM-CSF IL-8 PCR GM-GSF PCR
CXM 10 mg/l + n = 11 n = 11 - -
25 mg/l + n = 17 n = 17 - -
62.5 mg/l + n = 11 n = 11 n = 11 n = 10
62.5 mg/l - n = 11 n = 11 n = 11 n = 10
AZM 0.5 mg/l + n = 12 n = 10 - -
1.0 mg/l + n = 12 n = 10 - -
1.5 mg/l + n = 12 n = 10 n = 10 n = 11
1.5 mg/l - n = 11 n = 8 n = 11 n = 11
LVX 1 mg/l + n = 12 n = 11 - -
4 mg/l + n = 16 n = 18 - -
8 mg/l + n = 11 n = 11 n = 11 n = 11
8 mg/l - n = 10 n = 11 n = 11 n = 11
MXF 1 mg/l + n = 24 n = 22 - -
4 mg/l + n = 25 n = 23 - -
8 mg/l + n = 23 n = 23 - -
16 mg/l + n = 14 n = 14 n = 14 n = 14
8 mg/l - n = 11 n = 11 n = 11 n = 11Page 3 of 8
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CTG CTG CTG AGA TGA ATG AAA CAG TAG-3', Reverse:
5'-TGG ACT GGC TCC CAG CAG TCA AAA GGG ATG-3',
(size of PCR product: 286 bp).
Each 50- μl reaction mixture consisted of 5 μl of 10× PCR
buffer, 1.5 μl MgCl2 (~1.5 mM), 1 μl of 10 mM dNTP mix,
5 μl of specific primer for GAPDH, the mediators (synthe-
sized by MWG-Biotech, Germany) (~10 μM), 0.25 μl of
Taq DNA Polymerase (GIBCO, Germany) (~2 U), and
37.25 μl of H2O. The cycles (Peltier Thermal Cycler, MJ
Research, USA) used were as follows: GAPDH: 94°C for 3
min/94°C for 45 sec/60°C for 30 sec/72°C for 90 sec for
25 cycles, followed by an extension step of 10 min at
72°C. The same cycle conditions were used for the medi-
ators. The annealing temperature and PCR cycles for the
mediators were as follows: IL-8 58°C for 35 cycles; GM-
CSF 65°C for 40 cycles.
Products of amplification were transferred on a 2% agar-
ose gel and after electrophorese viewed using a 300-nm
ultraviolet transluminator (Cybertech, Germany). Sam-
ples from RT reactions that did not contain RT served as
negative controls. For quantification, PCR bands were
stained with ethidium bromide (Sigma, Germany) and
signal intensity was measured with an ultraviolet densito-
meter (Cybertech, Germany). Densitometric values are
expressed as the ratio of IL-8/GAPDH and GM-CSF/
GAPDH.
Statistical analysis
All statistical analyses were performed with SPSS 11.5
(Chicago, USA). The results are expressed as mean values
± SEM. We applied a non-parametric Wilcoxon-Test in our
exploratory analysis. Conventionally, p < 0.05 was con-
sidered significant. The correlations of the data obtained
by ELISA and PCR were calculated using the Pearson's test.
Results
Effects on spontaneous IL-8 release
Spontaneous IL-8-release of hu-BEC in ALI cultures was
44.7 ± 4.3 ng/ml. No significant changes were observed
with CXM (62.5 mg/l), AZM (1.5 mg/l), and LVX (8 mg/
l). After 24 h incubation with MXF (8 mg/l) IL-8 release
was reduced by 37 ± 20% (p < 0.008) (fig. 2).
Effects on TNF-α stimulated IL-8 release
Stimulation with TNF-α resulted in a 3.4-fold increase of
IL-8 release to 160.2 ± 6.4 ng/ml (p < 0.001). Incubation
with cefuroxime at a concentration of 62.5 mg/l led to a
significant further increase of IL-8 release in stimulated
hu-BEC by 33 ± 6% (p < 0.013). Under stimulated condi-
tions azithromycin showed a significant reduction of IL-8
production up to 16 ± 8% at a concentration of 1.5 mg/l
(p < 0.016). No significant changes were observed with
levofloxacin at concentrations of 1, 4, and 8 mg/l. Incuba-
tion with moxifloxacin led to a concentration dependent
reduction of IL-8 release to a maximum of 39 ± 7% (p <
0.001) at a concentration 16 mg/l (see Fig. 3).
Effects on spontaneous GM-CSF release
Spontaneous GM-CSF-release of hu-BEC in ALI cultures
was 654 ± 108 pg/ml. Incubation with CXM, AZM, or LVX
did not show a significant effect on GM-CSF release with
all concentrations tested. Only MXF reduced GM-CSF
release by 45 ± 31% (p < 0.004) (see Fig. 4).
Effects on TNF-α stimulated GM-CSF release
Stimulation with TNF-α did not significantly alter GM-
CSF release from hu-BEC in ALI cultures (maximum effect
+17 ± 7%, n.s.). GM-CSF release of TNF-α stimulated hu-
Effect of cefuroxime (CXM), azithomycin (AZM), levo-floxacin (LVX) and moxifloxacin (MXF) on spontane us IL-8 rel se rom hu-BE,*p < 0.05 vs. c ntrolFigur  2
Effect of cefuroxime (CXM), azithomycin (AZM), lev-
ofloxacin (LVX) and moxifloxacin (MXF) on sponta-
neous IL-8 release from hu-BE,*p < 0.05 vs. control.
Effect of cefuroxime (CXM), azithomycin (AZM), levo-floxacin (LVX) and moxifloxacin (MXF) on TNF-α-stimulated IL-8-release; * p < 0.05 vs. controlFigu  3
Effect of cefuroxime (CXM), azithomycin (AZM), lev-
ofloxacin (LVX) and moxifloxacin (MXF) on TNF-α-
stimulated IL-8-release; * p < 0.05 vs. control.Page 4 of 8
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by incubation with different concentrations of CXM,
AZM, or LVX. Only MXF inhibited GM-CSF release in
TNF-α-stimulated hu-BEC with an inverse concentration
response characteristic (fig. 5). MXF concentration of 4
mg/l reduced GM-CSF release by 35 ± 24% (p < 0.009),
MXF 8 mg/l reduced GM-CSF release by 30 ± 23% (p <
0.013), and MXF 16 mg/l reduced GM-CSF release by 22
± 31% (p < 0.019) (fig. 5).
PCR Analyses
Spontaneous IL-8 mRNA/GAPDH ratio was 1.2 ± 0.06 in
the semi-quantitative PCR. The IL-8 mRNA/GAPDH ratio
was reduced by 21 ± 8% after incubation with 8 mg/l MXF
in unstimulated cells. Smaller effects were observed with
CXM, AZM, or LVX (all n.s.).
In TNF-α stimulated hu-BEC IL-8 mRNA/GAPDH ratio
increased to 1.54 ± 0.06 (p < 0,001). Incubation with
CXM, AZM, LVX, or MXF led to maximal changes of IL-8/
GAPDAH ratio of -15 ± 8%, +5 ± 12%, -8 ± 10%, and -11
± 7%, respectively (all n.s.).
The spontaneous and TNF-α stimulated GM-CSF/
GAPDH-ratio of hu-BEC in ALI cultures was 1.64 ± 0.08
and 1.81 ± 0.08, respectively. Incubation with CXM, AZM,
LVX, or MXF did not significantly alter GM-CSF/GAPDH-
ratio at all concentrations investigated (n.s.).
Correlation analysis revealed weak correlations between
IL-8 protein as measured by ELISA and IL-8 m-RNA/
GAPDH ratio (r = 0.373, p < 0.001) as well as between
GM-CSF protein and GM-CSF mRNA/GAPDH ratio (r =
0.209; p < 0.004).
Discussion
The data presented here demonstrate that some antibiot-
ics are capable of modifying the inflammatory activation
of human bronchial epithelial cells. The differential
effects observed between different groups of antibiotics
suggest that the member of the cephalosporine group
cefuroxime do not show this effect, whereas azithromycin
and moxifloxacin exert anti-inflammatory effects on hu-
BEC, with moxifloxacin suppressing IL-8 and GM-CSF
with and without TNF-α stimulation in our experimental
setting, whereas AZM decreased IL-8 only after stimula-
tion with TNF-α and had no significant effect on GM-CSF.
Immunomodulatory effects of antibiotics have been
described so far in vivo with animal models, in vitro with
models of immune cells, NHBE cells (normal human
bronchial epithelial cells) and immortalised respiratory
cell lines [1,4-7]. In those experiments it could be demon-
strated that MXF leads to a reduction of IL-8, TNF-α, IL-
1α, IL-1β, IL-4 and IFN-γ in monocytes, lymphocytes and
neutrophils after stimulation with different agents. The
direct effect on GM-CSF has not been investigated yet in
cells of the immune system. However, in a mouse model
of bone-marrow ablation with cyclophosphamide MXF
leads to an increase of WBC and GM-CSF was augmented
in the lungs of these mice [25]. In contrast, our findings
suggest that MXF reduces spontaneous and TNF-α stimu-
lated GM-CSF production and release of hu-BEC. This
could be related to the different models and the different
stimuli used.
For lung cells, only data of A549 cells, an immortalized
type II alveolar epithelial cell line and IB3 cells, a cystic
fibrosis cell line, are published [5,6]. In IB 3 cells MXF
Effect of cefuroxime (CXM), azithomycin (AZM), levo-floxacin (LVX) and moxifloxacin (MXF) on spontane us GM-CSF release f m hu-BE,*p < 0.05 vs. co trolFigu  4
Effect of cefuroxime (CXM), azithomycin (AZM), lev-
ofloxacin (LVX) and moxifloxacin (MXF) on sponta-
neous GM-CSF release from hu-BE,*p < 0.05 vs. 
control.
Effect of cefuroxime (CXM), azithomycin (AZM), levo-floxacin (LVX) and moxifloxacin (MXF) on TNF-α-stimulated GM-CSF-r lease; * p < 0.05 vs. controlFigure 5
Effect of cefuroxime (CXM), azithomycin (AZM), lev-
ofloxacin (LVX) and moxifloxacin (MXF) on TNF-α-
stimulated GM-CSF-release; * p < 0.05 vs. control.Page 5 of 8
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A549 cells MXF decreases NO production and NF-κB-acti-
vation [5]. Our study demonstrates anti-inflammatory
effects of quinolones in a human ex vivo model of primary
bronchial epithelial cells. The concentrations of the differ-
ent antibiotics employed were comparable to concentra-
tions reached by therapeutic medication in humans.
Using primary hu-BEC in ALI cultures and therapeutically
relevant concentrations of different antibiotics suggest
that these findings may be also clinically relevant and may
have implications for the treatment of human lung
diseases.
In our study, we investigated the effect of different antibi-
otics on IL-8 and GM-CSF after application of TNF-α as an
inflammatory stimulus. TNF-α is a proinflammatory
cytokine with pro-fibrotic features which has a key role in
lower respiratory tract infections as well as in chronic
inflammatory lung disease like asthma, bronchiolitis
obliterans, or COPD [11,26,27]. A blockade of TNF-α led
to decrease of IL-8 after stimulation with LPS in lungs of
patient with COPD [27].
Similarly, IL-8 and GM-CSF are key mediators not only in
acute infectious inflammation but also in chronic inflam-
mation as observed in COPD, bronchial asthma, and
bronchiolitis obliterans [24,26,28]. IL-8 is rapidly
induced by an inflammatory stimulus like TNF-α or LPS
and is one of the most potent neutrophil chemoattract-
ants in human tissue [27,29]. GM-CSF leads to an activa-
tion and increased survival of leukocytes and enhance
oxidative burst in the lungs, thus maintaining and pro-
longing inflammatory reactions [28].
As we and other have shown, IL-8 and GM-CSF are
secreted locally by the respiratory epithelium [24-
26,28,30]. However, there is no specific treatment yet in
humans to directly address and modify these cytokines to
suppress the inflammatory cascade.
Our observations suggest that some antibiotics may have
the capability to block or modulate this inflammation. In
our experiments we employed concentrations of AZM,
LVX and MXF which were comparable to therapeutic con-
centrations of these antibiotics and are reached in human
lungs in vivo [8,9]. The serum level after therapeutic doses
of MXF and LVX is 1-5 mg/l and after oral administration
concentrations reached in the epithelial lining fluid (ELF)
are 5 - 7 times higher than serum levels [9]. After oral
administration with AZM serum level is 0.10 mg/l and the
concentration in the ELF ranges from 0.94 mg/l to 1.2 mg/
l after oral administration [8]. However, AZM accumu-
lates intracellulary in alveolar macrophages with a con-
centration of 205.24 mg/l 24 hours after the last intake
under steady state conditions [8,10]. The concentration of
cefuroxime used in our experiments covers a range of
serum and intrapulmonary concentrations after oral and
continuous i.v. administration in humans [31-34]. Addi-
tionally we used a concentration of cefuroxime (62.5 mg/
L) above these therapeutic intrapulmonary
concentrations.
So far AZM and other macrolides are the only antibiotics
used for therapeutic modulation of the local immune sys-
tem in the lung. A beneficial effect of AZM has been dem-
onstrated in the management of cystic fibrosis lung
disease and diffuse panbrochiolitis (DPB) [2,3,18]. DPB is
a disease observed predominantly in Asia, which without
medical intervention leads to a rapid decline of lung func-
tion and death [3]. AZM is also used for treatment of
bronchiolitis obliterans after organ transplantation, a
chronic inflammatory and fibroproliferative disease lead-
ing to bronchiolar obstruction and obliteration of distal
airspaces after lung transplantation but also after haemat-
opoetic stem cell transplantation [35,36]. In our experi-
ments only AZM at a concentration of 1.5 mg/l was
associated with a significant reduction of IL-8 release.
These findings differ from results in NHBE cells, a human
bronchial epithelial cell line, where AZM at a concentra-
tion of 1.0 mg/l did not show an effect, whereas at a con-
centration of 10 mg/l an increase in IL-8-secretion was
observed [37]. However, in vivo a concentration of 10 mg/
l cannot be found under steady state conditions in ELF of
the normal lung and was, therefore, not investigated in
our experiments with hu-BEC. Hence, the immunomodu-
latory effects mediated by macrolides may not only
depend on a direct effect on lung epithelial cells, but also
on a direct effect on alveolar macrophages because of the
intracellular accumulation in alveolar macrophages.
We also investigated effects on IL-8 mRNA and GM-CSF
mRNA expression. In general the mRNA expressions of
both, IL-8 and GM-CSF, were correlated with IL-8 and
GM-CSF protein release, thus supporting the view that
changes in protein release were related to changes in gene
expression. However, the differences in mRNA expression
between different experimental groups were not statistical
significant. This could be due to the fact that changes of
gene expression may be transient and are less well
detected after 24-hours of incubation, when the cells were
lysed and the mRNA isolated. In this respect further stud-
ies are needed to quantify the effect on mRNA-levels at
earlier time points.
Although our data suggests that quinolones exert anti-
inflammatory effects on hu-BEC, these effects are not uni-
form for all quinolones. In our experiments, moxi-
floxacin, a quinolone with a cyclopropyl-moiety at N1
(like ciprofloxacin) had a more pronounced effect on
cytokine release when compared to levofloxacin, a qui-Page 6 of 8
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the above-mentioned anti-inflammatory effects a careful
use of quinolones is recommended due to risk of cross-
resistance.
Several intracellular signal transduction pathways mecha-
nisms are thought to be responsible for these anti-inflam-
matory effects [1,4-6]. Yet these mechanisms are not
completely understood. Previous studies have shown that
pre-treatment with MXF leads to an inhibition of the
MAP-Kinases ERK 1/2 and JNK in monocytes [4,38]. MXF
also inhibits the phosphorylation of these kinases in IB3
cells, C38 cells and A549 cells [5,6]. In contrast, the MAP-
kinase p38 was not influenced by MXF [6]. Additionally,
in monocytes and respiratory cell lines MXF inhibits NF-
κB-activation due to reduced Iκ-B degradation [38]. This
prevents NF-κB activation and translocation to the
nucleus and thus inhibits the cytokine cascade.
Conclusion
Our data confirm previous studies showing a significant
inhibitory effect of quinolones with a cyclopropyl-moiety
at N1 on cytokine release. Our study adds new aspects by
using primary hu-BEC in ALI cultures and by employing
therapeutically relevant concentrations of different antibi-
otics. When compared to MXF, AZM showed smaller
effects on IL-8 release and did not affect GM-CSF release
in concentration which can be reached in human ELF. In
contrast, LVX showed no significant effects on cytokine
release and CXM led to an increase in IL-8 release. There-
fore, MXF appears to be more potent as an anti-inflamma-
tory substance in bronchial epithelial cells. However, the
clinical relevance of these findings has not been evaluated
yet.
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